X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
CR845 (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under clinical development for the treatment of moderate-to-severe pruritus in patients with Atopic Dermatitis.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: CR845
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Cara intends to use the proceeds from the agreement to support the ongoing clinical development of its oral CR845 (difelikefalin) pipeline, including late-stage programs for pruritus associated with atopic dermatitis, advanced chronic kidney disease, and notalgia paresthetica.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: CR845
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: HealthCare Royalty
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 02, 2023
Details:
Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Maruishi Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Kapruvia® (difelikefalin) is a selective kappa opioid receptor agonist with low central nervous system penetration. It is recommended by NICE for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
Lead Product(s): Difelikefalin
Therapeutic Area: Nephrology Product Name: Kapruvia
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
CR845 (difelikefalin) is an oral agonist of kappa opioid receptors (KORs) It is being developed for the treatment of pruritus secondary to chronic kidney disease and notalgia paresthetica.
Lead Product(s): Difelikefalin
Therapeutic Area: Neurology Product Name: CR845
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Enteris Biopharma Inc
Deal Size: $46.0 million Upfront Cash: $8.0 million
Deal Type: Licensing Agreement October 10, 2022
Details:
The primary efficacy endpoint of change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 8 was achieved for Korsuva (difelikefalin) vs. -2.4 placebo, p=0.001.
Lead Product(s): Difelikefalin
Therapeutic Area: Neurology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
KOMFORT Phase 2 clinical trial evaluating oral Korsuva (difelikefalin) for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica will be presented during a late-breaking news session.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Kapruvia
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
